You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石药业-B(02616.HK)与LCB就抗体偶联药物LCB71订立授权协议
格隆汇 10-29 06:56

格隆汇 10 月 29日丨基石药业-B(02616.HK)发布公告,2020年10月28日,公司与LegoChem Biosciences, Inc.(“LCB”或“许可方”)订立授权协议,据此,许可方授予独家许可以允许公司(“被许可方”)于韩国境外地区开发并商业化LCB71,一种以受体酪氨酸激酶样孤儿受体1(“ROR1”)为靶点的临床前阶段抗体偶联药物(“ADC”)。

根据授权协议并按照其中的条款及条件,许可方有权就开发、监管及商业里程碑收取总额为1000万美元的预付款及总额为3.535亿美元的或然付款。此外,许可方有权收取基于LCB71净销售额的分层特许权使用费。签立授权协议后,公司将负责承担于韩国境外地区LCB71所有正在进行的以及未来试验有关的开发和监管事务相关活动的所有费用。根据授权协议,公司须遵守惯常的排他性不竞争义务,而许可方和被许可方须遵守惯常的相互陈述、保证、契约和弥偿保证。

ROR1在多种癌症中都有高表达,包括各类白血病、非霍奇金淋巴瘤、乳腺癌、肺癌及卵巢癌。LCB71具有专有的肿瘤激活的吡咯并苯二氮卓(“PBD”)前毒素,可解决与传统PBD载荷有关的典型毒性问题。LCB71已在几种临床前癌症模型中证明具有完全的肿瘤抑制作用,这或将会转化为多种实体和血液恶性肿瘤的广泛治疗指标。此外,LCB71利用定向偶联技术获得精准的药物抗体比率,有效地支持药物血清半衰期并改善其药代动力学特性,也便于实现均质生产及大规模生产。公司确信与LCB订立的授权协议以新模式加强了基石的精准治疗产品管线,并通过在新兴及具备巨大发展潜力的ADC领域中取得这款潜在的同类首创╱ 同类最优资产的全球性权利,推进其管线2.0战略。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account